| Year |
Citation |
Score |
| 2019 |
Zhu Y, Smith DJ, Zhou Y, Li YR, Yu J, Lee D, Wang YC, Di Biase S, Wang X, Hardoy C, Ku J, Tsao T, Lin LJ, Pham AT, Moon H, et al. Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer. Cell Stem Cell. PMID 31495780 DOI: 10.1016/J.Stem.2019.08.004 |
0.339 |
|
| 2017 |
Zhu Y, Bassoff N, Reinshagen C, Bhere D, Nowicki MO, Lawler SE, Roux J, Shah K. Bi-specific molecule against EGFR and death receptors simultaneously targets proliferation and death pathways in tumors. Scientific Reports. 7: 2602. PMID 28572590 DOI: 10.1038/S41598-017-02483-9 |
0.368 |
|
| 2015 |
Zhu Y, Choi SH, Shah K. Multifunctional receptor-targeting antibodies for cancer therapy. The Lancet. Oncology. 16: e543-54. PMID 26545843 DOI: 10.1016/S1470-2045(15)00039-X |
0.303 |
|
| 2015 |
Redjal N, Zhu Y, Shah K. Combination of systemic chemotherapy with local stem cell delivered S-TRAIL in resected brain tumors. Stem Cells (Dayton, Ohio). 33: 101-10. PMID 25186100 DOI: 10.1002/Stem.1834 |
0.328 |
|
| 2012 |
van de Water JA, Bagci-Onder T, Agarwal AS, Wakimoto H, Roovers RC, Zhu Y, Kasmieh R, Bhere D, Van Bergen en Henegouwen PM, Shah K. Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects. Proceedings of the National Academy of Sciences of the United States of America. 109: 16642-7. PMID 23012408 DOI: 10.1073/Pnas.1202832109 |
0.352 |
|
| 2011 |
Lee SH, Jia S, Zhu Y, Utermark T, Signoretti S, Loda M, Schaffhausen B, Roberts TM. Transgenic expression of polyomavirus middle T antigen in the mouse prostate gives rise to carcinoma. Journal of Virology. 85: 5581-92. PMID 21411524 DOI: 10.1128/Jvi.02609-10 |
0.466 |
|
| Show low-probability matches. |